News
Rocket Pharmaceuticals Announces Appointment Of Aaron Ondrey As Chief Financial Officer And Additional Updates To Corporate Leadership Team
26 Mar 24
News, Management
UBS Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $54
1 Mar 24
News, Price Target, Analyst Ratings
JP Morgan Maintains Overweight on Rocket Pharmaceuticals, Lowers Price Target to $50
27 Feb 24
News, Price Target, Analyst Ratings
Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target
27 Feb 24
News, Price Target, Analyst Ratings
Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $53 Price Target
13 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Rocket Pharmaceuticals Announced The FDA Has Extended The Priority Review Period For Kresladi Application For Severe Leukocyte Adhesion Deficiency-I, By Three Months To June 30, 2024
13 Feb 24
Biotech, News, Health Care, FDA, General
Cantor Fitzgerald Reiterates Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target
31 Jan 24
News, Price Target, Reiteration, Analyst Ratings
Press releases
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
26 Mar 24
Press Releases
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
5 Mar 24
Small Cap, Opinion, Press Releases
Thinking about trading options or stock in Snowflake, Palantir Technologies, Rocket Pharmaceuticals, Fortinet, or Marathon Digital?
1 Mar 24
Opinion, Press Releases
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADIā¢ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
13 Feb 24
Press Releases
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
2 Jan 24
Press Releases